SMC commitment to ensuring patients' voices are heard in HTA underlined by rise in submissions

A rise in the number of medicines that are accompanied by a patient group submission has underlined SMC's commitment to ensuring the voice of patients are heard in the health technology assessment (HTA) process.

In 2018, 93% (61) of the medicines we assessed featured a patient group submission, up from 87% (54) in 2017.

The figures feature in an end of year flash report put together by our Public Involvement team, who support patient groups to take part in SMC's work.

Read the report